There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND , Sept. 17, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced grants of stock options and restricted stock units to several new officers and
Toggle Summary Acibadem Maslak Hospital in Turkey Introduces Next Generation Cancer Care with MRIdian MR-Image Guided Radiation Therapy
Breakthrough Technology Enables High-Definition Soft Tissue Visualization and Real-Time Image Guidance During Beam Delivery CLEVELAND , Sept. 13, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with
Toggle Summary ViewRay® to Participate in Upcoming Conferences
CLEVELAND , Aug. 31, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to participate in two upcoming investor conferences. The Company will first participate in a fireside chat at the B.
Toggle Summary ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
CLEVELAND , Aug. 17, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.


ViewRay Headquarters

2 Thermo Fisher Way
Oakwood Village, Ohio 44146 +1 (440) 703-3210